Anti-CD22/CD19 monoclonal antibody-toxin conjugate

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD22/CD19 monoclonal antibody-toxin conjugate
Drug Alias NameCombotoxCombotox N97A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Toxin
Mechanisms of ActionCD22 modulatorsProtein biosynthesis inhibitorsAnti-CD19
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Texas Southwestern Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterGalileo Research
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A